Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds. When compared with trastuzumab, the antibody of the present disclosure exhibits better killing ability for HER2-unexpressed cancer cells which have non-reactivity (or resistance) to the trastuzumab antibody or have reduced sensitivity. In addition, when the anti-HER2 antibody of the present disclosure is administered in combination with trastuzumab, a synergistic killing ability is achieved for cancer cells on which the trastuzumab antibody acts.

Abstract: The present disclosure relates to a binder solution having lithium ion conductivity for an all-solid-state battery and an electrode slurry including the same. Specifically, the binder solution includes a first binder having high binding force, a second binder having higher lithium ion conductivity than that of the first binder, a lithium salt, and an organic solvent that dissolves the lithium salt.

Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds. When compared with trastuzumab, the antibody of the present disclosure exhibits better killing ability for HER2-unexpressed cancer cells which have non-reactivity (or resistance) to the trastuzumab antibody or have reduced sensitivity. In addition, when the anti-HER2 antibody of the present disclosure is administered in combination with trastuzumab, a synergistic killing ability is achieved for cancer cells on which the trastuzumab antibody acts.

Abstract: The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19, and thus may be utilized as a CAR-immune cell therapeutic agent.

Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.

Abstract: The present invention generally relates to a structure of an optical digital pen. In particular, the invention relates to an optical digital pen by use of light scattering which can effectively acquire positional information of a pen tip even when the optical digital pen moves at a tilt on a display panel having a smooth surface. The invention is advantageous in that even when an optical digital pen is used at a tilt on a panel having a smooth surface made of glass or transparent plastic, reflected light for acquiring positional information of a pen tip is sufficiently received. In addition, the optical digital pen has an advantage of being compatibly used with a display panel of an electronic device such as a tablet PC or a laptop computer.

Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.

Abstract: Provided is a method of compressing an occupancy map of a three-dimensional (3D) point cloud, and more specifically, a method of compressing an occupancy map of a point cloud in which an occupancy map image of a point cloud existing in a 3D space is compressed based on a compression quality or a patch-by-patch inspection method of the occupancy map image so that compression distortion is minimized when reconstructing the compressed occupancy map image so as to remarkably improve the quality of a reconstructed occupancy map image.

Abstract: The present invention relates to an injector, a combustor comprising same, and a gas turbine comprising same. The injector comprises: an injector body; and a slit portion formed through the injector body in a reference direction, wherein the slit portion comprises: a first slit portion having a shape extending along the circumferential direction of a virtual reference circle having a virtual reference axis extending in the reference direction as a center thereof; and a second slit portion having a shape extending in the radial direction of the reference circle.

Abstract: A filtration device includes: a filtration tank having a raw water inlet pipe and a backwash water discharge pipe connected to an upper portion thereof, and a treated water discharge pipe, a backwash water inlet pipe, and a backwash air inlet pipe connected to a lower portion thereof; a strainer provided in the filtration tank and having a plurality of water passage holes formed on a side surface thereof and a lower side in communication with the treated water discharge pipe; a filtration unit including a fiber filter medium forming a filtration pore layer on the outer circumferential surface of the strainer, an upper support portion coupled to an upper side of the fiber filter medium, and a lower support portion coupled to a lower side of the fiber filter medium; and a filtration control unit having a cylinder disposed inside the strainer and a piston elevating from the cylinder and controlling the porosity of the fiber filter medium by compressing or relaxing the fiber filter medium with respect to the stra

Abstract: Disclosed are a binder solution for an all-solid-state battery including a binder in the form of particles, and a method of manufacturing the same. The binder solution may include a rubber-based binder, a first solvent for dissolving the rubber-based binder, and a second solvent in which the rubber-based binder is insoluble and which is miscible with the first solvent.

Abstract: The present invention generally relates to a structure of an optical digital pen. In particular, the invention relates to an optical digital pen by use of light scattering which can effectively acquire positional information of a pen tip even when the optical digital pen moves at a tilt on a display panel having a smooth surface. The invention is advantageous in that even when an optical digital pen is used at a tilt on a panel having a smooth surface made of glass or transparent plastic, reflected light for acquiring positional information of a pen tip is sufficiently received. In addition, the optical digital pen has an advantage of being compatibly used with a display panel of an electronic device such as a tablet PC or a laptop computer.

Abstract: The present disclosure relates to a binder solution for an all-solid-state battery and an all-solid-state battery comprising the same and having a uniform binder distribution. The binder solution may comprise: a binder including a fluorine-based polymer; a first solvent; and a second solvent. A Hansen solubility index difference value (Ra) between the fluorine-based polymer and the first solvent is about 10 or less, and a Hansen solubility index difference value (Ra) between the first solvent and the second solvent is about 7 or less.

Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.

Abstract: The present invention relates to: a novel antibody or an antigen-binding fragment thereof for use in the treatment of cancer by targeting B cell malignancies; a chimeric antigen receptor comprising the same; and uses thereof. The antibody of the present invention is an antibody specifically binding to CD19 highly expressed in cancer cells (particularly, blood cancer) and has very low homology compared to the CDR sequences of conventional CD19 target antibodies, and thus the sequence thereof is unique. In addition, cells expressing a chimeric antigen receptor comprising an anti-CD19 antibody or antigen-binding fragment of the present invention induce immune cell activity in response to a positive cell line expressing CD19, and thus can be usefully used as a therapeutic agent for CAR-immune cells.

Abstract: The present disclosure relates to a binder for an all-solid-state battery, a method for preparing the binder, an electrode for an all-solid-state battery including the binder, and an all-solid-state battery including the electrode. Particularly, the binder for an all-solid-state battery has a three-dimensional network structure formed by mixing a polymer having unsaturated carbon double bonds, sulfur donor, vulcanization accelerator, first activating agent and a second activating agent in an adequate amount, and then carrying out heat treatment to perform crosslinking through the covalent bonding of carbon in the polymer chains with sulfur. In this manner, it is possible to minimize damages upon the sulfide-based solid electrolyte.

Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.

Abstract: The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19, and thus may be utilized as a CAR-immune cell therapeutic agent.

Abstract: The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19.

Abstract: Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.